Stereotactic aspiration plus subsequent thrombolysis for moderate thalamic hemorrhage

World Neurosurg. 2012 Jan;77(1):122-9. doi: 10.1016/j.wneu.2011.06.036. Epub 2011 Nov 10.

Abstract

Objective: This study aimed to evaluate the efficacy and safety of stereotactic aspiration combined with subsequent thrombolysis in treating moderate thalamic hemorrhage (TH).

Methods: A total of 105 patients with TH were nonrandomly assigned to the conservative treatment group (n = 60) or to the aspiration group (n = 45). Patients in the aspiration group were treated with stereotactic aspiration plus subsequent thrombolysis for removal for their hematomas.

Results: The 30-day mortality in the conservative group was significantly higher than that in the aspiration group (28.3% (17/60) vs. 11.2% (5/45), P = 0.032). The rank of the 30-day Glasgow outcome scale in the conservative group was significantly lower than that in the aspiration group (P = 0.041), and the mean 30-day National Institutes of Health Stroke Scale score of the survivors in the conservative group was significantly higher than that in the aspiration group (16.5 ± 4. 2 vs. 14.2 ± 3.9, P = 0.012). There were a greater reduction in TH volume in the aspiration group than in the conservative group from day 1 to day 3 (-0.24% and 39.28%, respectively, P < 0.0001) and from day 1 to day 7 (26.58% and 63.26%, respectively, P < 0.0001). The rank of 90-day Glasgow outcome scale was significantly lower in the conservative group than that in the aspiration group (P = 0.015). Eighteen of 60 patients (30.0%) had a favorable outcome in the conservative group, whereas 23 of 45 patients (51.1%) had a favorable outcome in the aspiration group, and this difference was significant (P = 0.028). The 90-day cumulative mortality rate in the conservative group was significantly higher than that in the aspiration group (33.3% (20/60)) vs. 15.6% (7/45), P = 0.039).

Conclusions: Stereotactic aspiration plus subsequent thrombolysis is effective and safe for moderate TH.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biopsy, Fine-Needle
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Follow-Up Studies
  • Glasgow Coma Scale
  • Glasgow Outcome Scale
  • Humans
  • Intracranial Hemorrhages / therapy*
  • Male
  • Middle Aged
  • Perioperative Care
  • Stereotaxic Techniques*
  • Suction / methods*
  • Thalamic Diseases / therapy*
  • Thrombolytic Therapy / methods*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Urokinase-Type Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Urokinase-Type Plasminogen Activator